Auricular Neurostimulation for Chemotherapy-Induced Nausea and Vomiting
Trial Summary
What is the purpose of this trial?
This study evaluates the efficacy of auricular percutaneous electrical nerve field stimulator in children, adolescents and young adults with chemotherapy induced nausea and vomiting.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. Please consult with the trial coordinators for more details.
What data supports the effectiveness of the treatment Auricular Neurostimulation for Chemotherapy-Induced Nausea and Vomiting?
Research shows that electrical stimulation, including auricular neurostimulation, can help reduce nausea and vomiting caused by chemotherapy. Studies have found that stimulating specific points, like the P6 point, can decrease the frequency and severity of these symptoms, providing relief for many patients.12345
Is auricular neurostimulation safe for humans?
How does auricular neurostimulation differ from other treatments for chemotherapy-induced nausea and vomiting?
Auricular neurostimulation is unique because it involves stimulating nerves in the ear using small electrical currents, which is different from traditional drug treatments or acupuncture methods. This approach targets specific nerve pathways to help reduce nausea and vomiting without the need for medication.13567
Eligibility Criteria
This trial is for children, adolescents, and young adults who are about to receive chemotherapy that's known to cause moderate or severe nausea and vomiting. They must have at least one more cycle of the same chemo planned. It's not for those with developmental delays affecting participation, ear infections or skin conditions, uncontrolled infections, electrical implants in their body, pregnancy, severe heart/lung disease, bleeding disorders or psoriasis vulgaris.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive active or sham auricular neurostimulation therapy for a maximum of 5 days during chemotherapy admission
Crossover Treatment
Participants cross over to the other group (active vs sham) during the next identical chemotherapy cycle
Follow-up
Participants are monitored for nausea, vomiting, and need for additional antiemetic support up to 7 days after completion of intervention
Treatment Details
Interventions
- Auricular percutaneous neurostimulation
- Sham percutaneous neurostimulation
Auricular percutaneous neurostimulation is already approved in United States for the following indications:
- Functional abdominal pain associated with irritable bowel syndrome (IBS) in pediatric patients
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical College of Wisconsin
Lead Sponsor